2025 WFA Annual Conference and Glaybox Global ART Industry Exchange concludes

2025-12-19 #WFA Annual

On 12 November 2025, the 2025 WFA Annual Conference and Glaybox Global ART Industry Exchange was held at the Beijing HNA Marriott, with 230 attendees.

On 12 November 2025, the 2025 World Fertility Industry Alliance (WFA) Annual Conference and the Glaybox Global ART Industry Exchange Conference was held at the Beijing HNA Marriott, drawing 230 attendees for discussion on technical advances, service upgrades, legal compliance, and cross-border cooperation.

WFA President Peng Wenlin, Secretary-General Dong, and council representatives Hu Yihan, Niu Jifang, Shi Meilin, and Zhang Qi delivered opening remarks, sharing how they have grown alongside the association and reviewing WFA's work over the two years since its founding.

The WFA Legal Advisory Committee was formally established at the conference, composed of senior legal experts including Che Tianchi and Deng Zhe, and dedicated talks were delivered on legal risk control in ART, judicial reasoning in frozen-embryo return disputes, and legal compliance systems for private enterprises.

The 2025 Global ART Industry Influence Brand and Outstanding Young Entrepreneur evaluation was announced at the same event, which attracted 350,000 visits and more than 130,000 valid votes, ultimately recognising 19 influence brands and 11 outstanding young entrepreneurs.

The influence-brand list: Glaybox Medical, Power IVF (Mexico), Dan Ruo International Fertility Hospital, Youyunxing, Dan Ruo Bangkok Fertility Center, Wei Lai Sheng, Youyisheng, Dachao & Dajing, INCINTA (USA), Chao Sheng Yuan, Glaybox Mei Yun (GFG), Hai Wei Pharma, Hai Doctor, Shi Guan Jia, UCFC Fertility Center (Colombia), Jia You San Hai, Chang Chun Teng International Gene Bank, Kao La Ma Ma, and TATE CARE.

The roundtable discussion centred on "Breaking through in overseas fertility business: challenges, change, and new opportunities."

This article is a public-information summary published by WFA. It is intended for industry, media and the general public, and does not constitute medical or investment advice.